JLJianbo Li

Jianbo Li

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Jianbo Li has a total of 40 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Preliminary assessment of biodistribution and targeting of the fluorescent molecular probe Cy7-SYL3C in an EpCAM-positive colorectal cancer mouse model

    by Yiwen Li, Min Li, Pinghui Li, Zhidie Huang, Xiang Liu, Xiaoyan Duan, Jianbo Li

    Molecular imaging probes targeting the epithelial cell adhesion molecule (EpCAM) hold considerable promise in advancing colorectal cancer (CRC) research. Building on previous work, this study further evaluated the biodistribution of Cy7-SYL3C in healthy mice and its targeting efficacy in HT-29 colorectal cancer models, confirming its potential as a near-infrared fluorescent (NIRF) imaging probe. The fluorescent molecular probe Cy7-SYL3C was synthesized by conjugating the Cy7 fluorophore to the 5’ end of the SYL3C aptamer. Biodistribution studies were conducted in healthy mice following intravenous administration of the probe. For tumor targeting evaluation, a subcutaneous HT-29 human CRC xenograft model was established in nude mice. Tumor-bearing mice were allocated into two groups: an experimental group and a pre-blocking group. The pre-blocking group received an excess of unlabeled SYL3C aptamer prior to injection of Cy7-SYL3C. Small animal in vivo imaging technology (SAFI) was employed to monitor the biological distribution and tumor targeting ability of Cy7-SYL3C at different time points from 5 min to 48 h after injection. The expression of EpCAM in tumor tissues was analyzed by Western blot. The targeting ability of the probe was evaluated through immunofluorescence co-localization and pre-blocking protocols. Cy7-SYL3C is mainly metabolized and cleared by the liver and kidneys. Fluorescence signals can be detected at the tumor site only 5 min after injection. Quantitative analysis showed that the average fluorescence intensity (AFI) at the tumor site in the experimental group was 88.2% higher (6.4 × 10 7 photons/s/mm 2 ) compared to the pre-blocking group (3.4 × 10 7 photons/s/mm 2 ) over a 4-hour observation period. Furthermore, the experimental group displayed a moderate positive correlation (Pearson’s r = 0.30 ± 0.02), in contrast to the negligible correlation observed in the pre-blocking group (Pearson’s r = 0.05 ± 0.01). The tumor-to-muscle ratio exceeded 1.0 at six hours post-injection and peaked at 1.30 ± 0.04 photons/s/mm 2 , with target-specific signals maintained for up to eight hours. This indicates that as the probe gradually removed from normal tissues such as muscles, it achieved sustained and specific retention at the tumor site. Combined with the significant reduction in the signal caused by the pre-blocking strategy, these results consistently indicated that the accumulation of Cy7-SYL3C in the body exhibited EpCAM targeting specificity. This study was based on the EpCAM targeting strategy and further evaluated the in vivo performance of the near-infrared fluorescent probe Cy7-SYL3C. The detailed dynamic imaging results at multiple time points indicated that this probe had a clear metabolic pathway in healthy mice and demonstrated rapid, sustained and specific tumor targeting ability in the HT-29 colorectal cancer model. These characteristics collectively confirmed the clinical application potential of Cy7-SYL3C as a high-performance molecular imaging tool in colorectal cancer research.

  • Open Access

    Pharmacokinetic Characterization of Single-Stranded DNA in Murine Models Using High-Specific-Activity 68 Ga Radiolabeling Coupled with Dynamic Positron Emission Tomography

    by Pinghui Li, Hao Wang, Zhidie Huang, Yiwen Li, Min Li, Dawei Jiang, Jianbo Li

    This study aimed to develop an efficient concentration methodology to enhance the specific activity of 68Ga. By systematically optimizing chelation parameters, we established the relationships between the molar amounts of single-stranded DNA (A20) and varying 68Ga specific activities, thereby maximizing the radiochemical yield in DNA radiolabeling systems. Method: The 68Ga eluate was subjected to ionic enrichment and initially purified using cation-exchange chromatography, followed by concentration through an organic/aqueous phase protocol employing acetone/NaCl eluents. Systematic chelation experiments were performed by reacting gradient concentrations of A20 (1 or 3 nmol) with radiometal solutions at defined specific activities (1, 5, and 10 mCi/mL). The resulting reaction mixtures were subsequently purified using PD-10 columns. Dynamic PET/CT imaging of the purified 68Ga-labeled A20 (68Ga-A20) was performed over a 60 min interval to assess its biodistribution and metabolic kinetics in murine models. Results: Extraction of 68Ga using water resulted in the introduction of sodium ions, which could interfere with subsequent labeling reactions. In contrast, acetone-based extraction effectively prevented contamination from exogenous ions. Optimization of the extraction protocol led to a 5-fold increase in the radioactivity concentration of 68Ga. Labeling studies demonstrated an efficiency of 75.03% when 3 nmol (100 μM) of A20 was used, and the 68Ga radioactivity concentration was maintained at 1 mCi/mL. Dynamic PET/CT imaging revealed that 68Ga-A20 was predominantly eliminated via the renal pathway in healthy mice. Following curve-fitting analysis, the calculated half-lives were 6.61 ± 0.26 min in blood, 13.53 ± 1.04 min in kidney, and 7.61 ± 0.27 min in liver. Conclusion: This study demonstrated that the radioactivity concentration of 68Ga can be effectively enhanced by processing the 68Ga solution through cation-exchange chromatography followed by acetone extraction, representing a critical advancement in improving radiolabeling efficiency. Additionally, the results indicated that 68Ga-A20 was primarily eliminated via the renal pathway in healthy mice.

  • Open Access

    Dynamic PET Imaging of EpCAM-Positive Colorectal Cancer Using Radiolabeled DTN-SYL3C Aptamer Conjugates

    by Zhidie Huang, Pinghui Li, Chengwen Zheng, Yiwen Li, Min Li, Xiaoyan Duan, Dawei Jiang, Jianbo Li

    DNA tetrahedra (DTN) could enhance the circulation and targeting capabilities of aptamers. This study constructs a gallium-68 (68Ga) radiolabeled DTN-SYL3C aptamer conjugate to evaluate their imaging potential for detecting epithelial cell adhesion molecule (EpCAM)-positive colorectal cancer (CRC). [68Ga]-Ga-DTN-SYL3C was prepared by hybridizing T20-DTN-SYL3C with [68Ga]-Ga-NOTA-ssDNA (A20) through base complementary pairing. Dynamic PET imaging was conducted in EpCAM-positive HT-29 tumor-bearing BALB/c nude mice using [68Ga]-Ga-DTN and [68Ga]-Ga-SYL3C as controls. T20-DTN-SYL3C was synthesized and characterized by agarose gel electrophoresis, while [68Ga]-Ga-DTN-SYL3C was verified by high-performance liquid chromatography (HPLC). The radiolabeling yield of [68Ga]-Ga-DTN-SYL3C was approximately 90%. Biodistribution studies indicated metabolism by the kidneys and liver. The blood half-life of [68Ga]-Ga-DTN-SYL3C was 11.39 ± 2.66 min, longer than that of [68Ga]-Ga-SYL3C (7.26 ± 0.17 min) in pharmacokinetic studies. Dynamic PET results showed tumor uptake of 0.89 ± 0.30%ID/g for [68Ga]-Ga-DTN-SYL3C, 0.27 ± 0.22%ID/g for [68Ga]-Ga-DTN, and 0.32 ± 0.16%ID/g for [68Ga]-Ga-SYL3C at 1 h (n = 3). In conclusion, the [68Ga]-Ga-labeled DTN-SYL3C aptamer conjugate effectively targets EpCAM-positive CRC and may serve as a promising imaging tool for detection and monitoring.


  • Open Access

    Emerging Applications of EpCAM-Targeted Nuclear Medicine Probes: Current Research and Future Perspectives

    by Zhidie Huang, Yiwen Li, Min Li, Xiang Liu, Xiaoyan Duan, Jianbo Li

    Molecular imaging in nuclear medicine has been employed extensively in recent years for tumor-targeted diagnosis and treatment that is attributed to its non-invasive property, which enables visualized functional localization. This functionality relies on the development of radionuclide molecular probes designed with the objective of identifying specific targets on the surface of tumors. Epithelial cell adhesion molecules (EpCAM) are considered to be a promising target as an antigenic marker for its widely present and integral to the processes associated with tumor occurrence and progression. This paper provides a comprehensive review of recent advancements in EpCAM-targeted radionuclide probes, focusing specifically on a range of primary ligands, including DARPins (Designed Ankyrin Repeat Proteins), antibodies, and aptamers, and evaluates the benefits and challenges, potential future directions of these radioactive probes.


  • Open Access

    SYL3C Aptamer-DNA Tetrahedra Conjugates Enable Near-Infrared Fluorescent Imaging of Colorectal Cancer

    by Zhidie Huang, Pinghui Li, Yiwen Li, Xiaoyan Duan, Mengting Li, Dawei Jiang, Jianbo Li

    Purpose: SYL3C is an optimized DNA aptamer with high selectivity and affinity for the epithelial cell adhesion molecule (EpCAM), an overexpressed tumor antigen in colorectal cancer (CRC). While its cellular affinity has been validated, in vivo studies are lacking. Methods: This study modifies SYL3C with the fluorescent motif Cy7 to evaluate its metabolism and diagnostic potential in EpCAM-positive HT-29 xenograft mice using near-infrared fluorescence (NIRF). We also employ DNA Tetrahedra (DTN) to load the Cy7-DTN-SYL3C probe and assess whether this strategy improves circulation and tumor uptake of SYL3C. Results: Cy7-SYL3C is primarily metabolized by the kidneys and enables targeted imaging of HT-29 tumors, outperforming untargeted Cy7-DTN. The DTN coupling strategy prolongs SYL3C metabolism and enhances tumor probe uptake about twice higher than Cy7-SYL3C over 24 hours. Conclusion: This study presents preliminary evidence for the SYL3C aptamer’s potential in vivo imaging of EpCAM-positive CRC. The DTN conjugation strategy may extend the aptamer’s metabolic stability and improve tumor uptake, expanding its applications in CRC diagnosis and treatment.


  • Open Access

    Glycyrrhizinate Monoammonium Cysteine-Loaded Lipid Nanoparticles Allow for Improved Acute Liver Injury Therapy

    by Yunjie Xu, Pinghui Li, Shiran Sun, Yulin Chen, Lixia Feng, Dawei Jiang, Chidan Wan, Jianbo Li, Xiong Cai

    Background: Acute liver injury (ALI) is a prevalent and potentially lethal condition globally, where pharmacotherapy plays a vital role. However, challenges such as rapid drug excretion and insufficient concentration at hepatic lesions often impede the treatment’s effectiveness. Methods: We successfully prepared glycyrrhizinate monoammonium cysteine (GMC)-loaded lipid nanoparticles (LNPs) using high-pressure homogenization. The characterization and safety of the LNPs were measured using electrophoretic light scattering (ELS), transmission electron microscopy (TEM), dynamic light scattering (DLS), cytotoxicity assays, and hemolysis tests. The distribution of LNPs in mice was explored using fluorescence labeling methods. The encapsulation efficiency of LNP-GMC was detected using High-Performance Liquid Chromatography (HPLC), and its slow-release effect on GMC was assessed through dialysis. The therapeutic effects of LNP-GMC and pure GMC on the ALI model were evaluated using fibroblast activation protein inhibitor (FAPI) PET imaging, blood biochemical indicators, and liver pathology slices. Results: The encapsulation of GMC in LNPs enhances drug stability and prolongs its hepatic retention, significantly improving its bioavailability and sustained release within the liver. This study also explores the expression of fibroblast activation protein (FAP) in ALI, employing 68Ga-FAPI PET/CT imaging for effective differentiation and assessment of liver injury. Conclusions: Our results suggest that LNPs offer an enhanced therapeutic approach for ALI treatment, reducing the required drug dosage, and 68Ga-FAPI PET/CT imaging provides a novel method for diagnosis and treatment assessment. This study contributes valuable insights into the utilization of LNPs in liver disease treatment, presenting a promising direction for future clinical applications.


  • Open Access

    PET image-guided kidney injury theranostics enabled by a bipyramidal DNA framework

    by Pinghui Li, Zhidie Huang, Xiaoyan Duan, Tao Wang, Shaowen Yang, Dawei Jiang, Jianbo Li

    We constructed 68 Ga-BDF and employed PET imaging to establish its pharmacokinetic model. BDF was eliminated from the body via the urinary system. We observed distinct imaging indicators in UUO and AKI mouse models. Furthermore, we observed the therapeutic effect of BDF on AKI.


  • Open Access

    Preliminary evaluation of a 64Cu-labeled DNA aptamer for PET imaging of glioblastoma

    by Pinghui Li, Chunmei Wang, Wenrui Wang, Xiaoyan Duan, Jianbo Li

    To develop a DNA aptamer-based PET tracer for imaging of glioblastoma. 5 mM of NOTA-AS1411, 60-min, and 37 °C were selected as the optimal condition for 64Cu radiolabeling of AS1411. 64Cu-NOTA-AS1411 remained stable in PBS and 100% mouse serum for at least six hours. From the PET images, 64Cu-NOTA-AS1411 tended to be excreted out through the kidneys and there was high tracer accumulation in the bladder. There was a higher tumor uptake in the AS1411 group than that in the control group. 64Cu-NOTA-AS1411 is a suitable potential PET tracer for imaging murine glioblastoma.


  • Open Access

    Radiolabeling and Preliminary Evaluation of 99mTc-Labeled DNA Cube Nanoparticles as Potential Tracers for SPECT Imaging [Corrigendum]

    by Xiaoyan Duan, Yiri Du, Chunmei Wang, Zhenfeng Zhao, Chao Li, Jianbo Li

    Corrigendum for the article Radiolabeling and Preliminary Evaluation of 99mTc-Labeled DNA Cube Nanoparticles as Potential Tracers for SPECT Imaging

  • Open Access

    Role of Gastric Microorganisms Other than Helicobacter pylori in the Development and Treatment of Gastric Diseases

    by Xiaoyan Duan, Ping Chen, Xiaoxia Xu, Meiling Han, Jianbo Li

    The microenvironment in the stomach is different from other digestive tracts, mainly because of the secretion of gastric acid and digestive enzymes, bile reflux, special mucus barrier, gastric peristalsis, and so on, which all contribute to the formation of antibacterial environment. Microecological disorders can lead to gastric immune disorders or lead to the decrease of dominant bacteria and the increase of the abundance and virulence of pathogenic microorganisms and then promote the occurrence of diseases. The body performs its immune function through innate and adaptive immunity and maintains microbial balance through the mechanism of immune homeostasis. Microecological imbalance can lead to the invasion of pathogenic microorganisms and damage mucosal barrier and immune system. The coexistence of gastric microorganisms (including viruses and fungi) may play a synergistic or antagonistic role in the pathogenesis of gastric diseases. Probiotics have the ability to compete with intestinal pathogens, increase the secretion of immunoglobulin A (IgA), stimulate the production of mucin, bacteriocin, and lactic acid, regulate the expression and secretion of cytokines, and regulate the growth of microbiota, which all have beneficial effects on the host microbial environment. At present, most studies focused on Helicobacter pylori, ignoring other stomach microbes and the overall stomach microecology. So, in this article, we reviewed advances in human gastric microecology, the relationship between gastric microecology and immunity or gastric diseases, and the treatment of probiotics in gastric diseases, in order to explore new area for further study of gastric microorganisms and treatment of gastric diseases.